AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
27.99
-0.08 (-0.29%)
Sep 18, 2024, 4:00 PM EDT - Market closed
AtriCure Revenue
AtriCure had revenue of $116.27M in the quarter ending June 30, 2024, with 15.21% growth. This brings the company's revenue in the last twelve months to $429.95M, up 17.57% year-over-year. In the year 2023, AtriCure had annual revenue of $399.25M with 20.84% growth.
Revenue (ttm)
$429.95M
Revenue Growth
+17.57%
P/S Ratio
3.04
Revenue / Employee
$358,294
Employees
1,200
Market Cap
1.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
Dec 31, 2019 | 230.81M | 29.18M | 14.47% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Brookdale Senior Living | 2.92B |
Teladoc Health | 2.61B |
Integra LifeSciences Holdings | 1.57B |
Avadel Pharmaceuticals | 95.15M |
Ocular Therapeutix | 61.10M |
Day One Biopharmaceuticals | 8.19M |
ATRC News
- 22 days ago - AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device - Business Wire
- 27 days ago - Sparrow Mortgage Partners with Calque to Introduce The Trade-In Mortgage - Business Wire
- 27 days ago - AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation - Business Wire
- 7 weeks ago - AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - AtriCure Reports Second Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference - Business Wire
- 7 weeks ago - AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care - Seeking Alpha
- 2 months ago - AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China - Business Wire